RVNC
Revance Therapeutics Inc
Halal Rating :
Last Price
$3.67
Last updated:
Market Cap
-
7D Change
11.55%
1 Year Change
-39.14%
Company Overview
Industries
Exchange
Next Earnings Date
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including DAXXIFY, the first and only FDA-approved long-acting neuromodulator for the treatment of frown lines. The company also develops products for cervical dystonia and other neuroscience-based therapeutics.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $59.88m | $98.87m | - | $6.73m | 0.00% | 6.81% |
| June 30, 2024 | $65.39m | $105.58m | - | $5.68m | 0.00% | 5.38% |
| March 31, 2024 | $51.94m | $104.02m | - | $5.26m | 0.00% | 5.05% |
Company Impact
Help us evaluate Revance Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.